Surrozen (SRZN) Accumulated Expenses (2020 - 2026)
Surrozen (SRZN) recorded quarterly Accumulated Expenses of $6.7 million in Q1 2026, down 14.7% quarter-over-quarter from $7.9 million in Q4 2025, and down 25.75% on a YoY basis from $9.1 million in Q1 2025.
Surrozen (SRZN) Accumulated Expenses (2020 - 2026) Analysis & Trends
Surrozen's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $6.7 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 25.75% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (down 25.75% YoY), while the FY2025 annual figure was $7.9 million, up 52.74% from the prior year.
- Accumulated Expenses was $6.7 million for Q1 2026 at Surrozen, down from $7.9 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $9.1 million in Q1 2025 to a low of $3.5 million in Q1 2024.
- Historically, Accumulated Expenses has averaged $5.3 million across 5 years, with a median of $4.9 million in 2022.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses surged 399.4% in 2022, then slumped 39.75% in 2023.
- A 5-year view of Accumulated Expenses shows it stood at $6.8 million in 2022, then plunged by 39.75% to $4.1 million in 2023, then rose by 25.55% to $5.2 million in 2024, then surged by 52.74% to $7.9 million in 2025, then declined by 14.7% to $6.7 million in 2026.
- The last three Accumulated Expenses figures came in at $6.7 million (Q1 2026), $7.9 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.75 Mn |
| Dec 31, 2025 | 7.91 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.19 Mn |
| Mar 31, 2025 | 9.09 Mn |
| Dec 31, 2024 | 5.18 Mn |
| Sep 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 3.64 Mn |
| Mar 31, 2024 | 3.49 Mn |
| Dec 31, 2023 | 4.13 Mn |
| Sep 30, 2023 | 3.95 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 5.32 Mn |
| Dec 31, 2022 | 6.85 Mn |
| Sep 30, 2022 | 6.13 Mn |
| Jun 30, 2022 | 6.01 Mn |
| Mar 31, 2022 | 4.93 Mn |
| Dec 31, 2021 | 8.66 Mn |
| Sep 30, 2021 | 8.50 Mn |
| Jun 30, 2021 | 1.54 Mn |